WEC
AEGR

Winslow Evans & Crocker’s Aegerion Pharmaceuticals AEGR Stock Holding History

Winslow Evans & Crocker’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-340
Closed -$4.62K – 1409
2015
Q3 		$4.62K Hold
340
– – ﹤0.01% 1053
2015
Q2 		$6.45K Hold
340
– – ﹤0.01% 1029
2015
Q1 		$8.9K Hold
340
– – ﹤0.01% 912
2014
Q4 		$7.12K Hold
340
– – ﹤0.01% 964
2014
Q3 		$11.3K Buy
+340
New +$10.6K ﹤0.01% 867
2014
Q1 		– Sell
-45
Closed -$3K – 1450
2013
Q4 		$3K Buy
+45
New +$3.44K ﹤0.01% 1257

Other funds holding AEGR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Winslow Evans & Crocker's AEGR Position: Q4 2015 in Review

Winslow Evans & Crocker sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2015, closing a stake of 340 shares — an estimated $4.62K sold.

Winslow Evans & Crocker first reported a position in AEGR in Q4 2013 and held it in 6 quarters. The position peaked at $11.3K in Q3 2014. 109 funds tracked by Wall St. Rank hold AEGR as of Q4 2015.

  • Winslow Evans & Crocker reported no remaining Aegerion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Winslow Evans & Crocker sold 340 Aegerion Pharmaceuticals shares in Q4 2015, an estimated $4.62K.
  • Winslow Evans & Crocker first reported a position in Aegerion Pharmaceuticals in Q4 2013 and held it in 6 quarters.
  • Winslow Evans & Crocker's Aegerion Pharmaceuticals position peaked at $11.3K in Q3 2014.
  • 109 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2015.

Based on Winslow Evans & Crocker's 13F filing for Q4 2015, filed 27 Jan 2016.